Adia Nutrition Inc. Announces Landmark Autism Spectrum Disorder Clinical Study Now Live on ClinicalTrials.gov

Core Insights - Adia Nutrition Inc. has launched a clinical study targeting Autism Spectrum Disorder (ASD), which is now live on ClinicalTrials.gov, representing a significant advancement in the company's research pipeline [1][4]. Group 1: Clinical Study Details - The clinical trial, titled "Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study," aims to enroll approximately 100 children aged 3-12 with confirmed ASD [3]. - The study will evaluate the potential benefits of intravenous glutathione combined with umbilical cord blood-derived stem cells and exosomes (AdiaVita) compared to glutathione alone, focusing on changes in Autism Treatment Evaluation Checklist (ATEC) scores [3]. - The trial includes a 24-month follow-up period, with patient recruitment expected to begin in January 2026 [3]. Group 2: Company Overview - Adia Nutrition Inc. is based in Winter Park, Florida, and specializes in regenerative medicine, particularly through its subsidiary Adia Med [1][6]. - The company generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments [7]. - Adia Nutrition is expanding its offerings to include insurance-billable wound care products and operates Adia Med clinics that specialize in various regenerative treatments [6][7]. Group 3: Strategic Vision - The CEO of Adia Nutrition emphasized the importance of rigorous and transparent research, indicating that this study will serve as a foundational model for additional clinical investigations planned for 2026 [5]. - The company is open to strategic partnerships to expand access to advanced stem cell solutions and encourages clinic owners and healthcare practitioners to integrate Adia's regenerative therapies into their practices [5].